Depends upon what many people are expecting. If good news, I expect it will be a bump to 45c and then will settle back to 38c pre FDA (pre escrow release) as traders take profit. Then a brief pause before people wake up to the idea that if the news is good, FDA is a shoe-in and the escrow factor may get less regard (ie less concern of a sell-off because 1. the escrow holders might be circumspect about letting them go at a bargain price and 2. there will be sufficient demand in this scenario (a sell-off into good news) to absorb a dump so the price will temporarily flatten/dip to 33-35c while CT et al gobble up the cheap offerings). Then the price will gradually climb to around 65c in anticipation of FDA approval, building into the share price a higher base from which to rise after FDA approval. So, all IMO, a bit of a rollercoaster ride to 31 July with a nice view at the end. I hold but none of this is of any consequence to me. Even the post FDA surge that is highly likely doesn't matter: it's the revenue/dividends I'm after (although I understand they may not eventuate if RAP gets bought out). If that happens, I can still look forward to a decent takeover price in the ballpark of what ClownTrader was talking about a few posts above.
If I can get a few more in the meantime at current prices, all the better.
GLTAH and non-H
- Forums
- ASX - By Stock
- RAP
- Telehealth on the rise
Telehealth on the rise, page-191
-
-
- There are more pages in this discussion • 2,884 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online